COMPANY UPDATE PT ENSEVAL PUTERA MEGATRADING TBK Ended Sept 30, 2017 (Unaudited)

Transcription

1 COMPANY UPDATE PT ENSEVAL PUTERA MEGATRADING TBK Ended Sept 30, 2017 (Unaudited)

2 TABLE OF CONTENT SECTION 1 ENSEVAL IN BRIEF 3 SECTION 2 BUSINESS OVERVIEW 8 SECTION 3 OPERATIONAL OVERVIEW 20 SECTION 4 FINANCIAL OVERVIEW 23 SECTION OVERVIEW 28

3

4 ENSEVAL IN BRIEF Integrated healthcare Distribution and Logistic services company through Service Excellence, Technology Driven and Strong Leadership. Established in October 1973 with the aim of managing the distribution function because of the separation of the distribution division from the marketing and production division of PT Kalbe Farma; On 1 August 1994, the Company listed its shares on the Jakarta Stock Exchange; The Company focuses its activities on distribution and trading services under 5 divisions: Pharmaceutical products sales and distribution, which comprised of patented medicines as well as generic medicines; Consumer products, non prescription medicine and nutrition sales and distribution; Medical equipment sales and distribution, which include marketing activities; Raw material sales and distribution, which include veterinary product; Healthcare services. 4

5 ENSEVAL IN BRIEF More than 40 years in business, Enseval constanly makes the best effort to obtain sustainable growth Incorporation of PT Enseval 1988 Incorporation of PT Arya Gupta Cempaka 1993 PT Arya Gupta Cempaka changed its name to PT Enseval Putera Megatrading 1994 PT Enseval Putera Megatrading Tbk conducted its Initial Public Offering 2003 Incorporation of PT Millenia Dharma Insani 2007 Incorporation of PT Enseval Medika Prima and PT Global Chemindo Megatrading 2008 Incorporation of PT Renalmed Tiara Utama 2011 The Company Right Issue to finance expansion 2012 Obtained ISO 9001:2008 certification 2014 Incorporation of PT Medika Renal Citraprima Renewed GDP certification, ISO 9001: 2008 & OHSAS 18001:

6 ENSEVAL IN BRIEF Become Market Leader Through high quality of information Technology system and competent human resources. Currently, the Company owns and operates 47 branches and 28 branches under subsidiaries and 29 sales offices located on Indonesia archipelago; The Company also owns 2 Regional Distribution Centers (RDC) located in Jakarta and Surabaya; For the information technology platform, the Company now is using Oracle E-Business Suite Release 12; Until the end of September 2017, the Company's operation supported by over than 5,000 employees. 6

7 2017 OVERVIEW AWARDS UNTIL SEPT 2017 INFOBANK Fastest Growing Company Awards INDONESIAN HUMAN CAPITAL STUDY FRONTIER - The Best Building and Managing Corporate Image. PHARMACEUTICAL DISTRIBUTOR. MEDICAL EQUIPMENT DISTRIBUTOR. ORACLE - EXA Trend-Setter Award. FROST & SULLIVAN - Indonesia Pharmaceutical Distributor of the year. Department of Animal Husbandry in East Java province - the best distributor of veterinary drug. HERMINA HOSPITAL GROUP - The Best Pharmaceutical Distributor. BETHESDA HOSPITAL YOGYAKARTA - The Best Pharmaceutical Distributor. NIVEA - The Best Weighted Distributor. Rekor Bisnis Indonesia - Pharmaceutical Distributor with the Most Outlet Coverage. The Most Powerful Distribution Performance EXTRA JOSS KOMIX 7

8 2017 OVERVIEW SERTIFICATION AZ/NZS ISO 9001:2008 Certified BS OHSAS 18001:2007 Certified Good Distribution Practices Certified (GDP) 41 branches, Cara Distribusi Obat yang Baik (CDOB Certified) 8

9

10 BUSINESS OVERVIEW NET SALES PER PRODUCTS UNTIL SEPT 30, 2017 *Description of net sales per products as describe below : Products Portfolio Net Sales (Rp) Consumer Products Prescription Medicine Non Prescription Medicine Raw Materials for Sale Medical Equipment Veterinary Products Health Care Services Total : Contribution to Total Net Sales (%) 42,88% 27,64% 15,89% 7,58% 5,78% 0,19% 0,04% 100,00% 10

11 BUSINESS OVERVIEW DESCRIPTION OF NET SALES PER PRODUCTS AND THE CONTRIBUTION 15,89% 5,78% 0,19% 0,04% 7,58% Consumer Products Prescription Medicine Non Prescription Medicine Raw Materials for Sale Medical Equipment Veterinary Products Health Care Services 27,64% 42,88% Net Sales September 2017 Rp14.564,58 billion 11

12 BUSINESS OVERVIEW ALL BUSINESS LINE OF THE COMPANY WERE GREW SIGNIFICANTLY *Growth of net sales per products as describe below : Products Portfolio Net Sales Sep 2017 (Rp) Net Sales Sep 2016 (Rp) Growth % Consumer Products ,88% Prescription Medicine ,55% Non Prescription Medicine ,41% Raw Materials for Sale ,52% Medical Equipment ,03% Veterinary Products ,37% Health Care Services ,49% Total : ,48% 12

13 BUSINESS OVERVIEW GROWTH OF NET SALES Sept 2016 VS Sept ,48% 2,88% 7,55% 2,41% 4,52% 8,03% 6,37% 12,49% Total Consumer Products Prescription Medicine Non Prescription Medicine Raw Materials for Sale Medical Equipment Veterinary Products Health Care Services Sep-16 Sep-17 13

14 BUSINESS OVERVIEW THE COMPANY S PRINCIPALS Prescription Non-Prescription Consumer Health Beauty 14

15 BUSINESS OVERVIEW THE COMPANY S PRINCIPALS MEDICAL DEVICE & DIAGNOSTIC 15

16 BUSINESS OVERVIEW THE COMPANY S PRINCIPALS RAW MATERIALS 16

17 BUSINESS OVERVIEW NATIONAL COVERAGE 74 FULL SERVICES BRANCHES & MORE THAN 200,000 DIRECT OUTLET COVERAGE RDC JAKARTA RDC SURABAYA 47 BRANCH 27 BRANCH under subsidiaries (TSJ) 29 SALES OFFICE 17

18 BUSINESS OVERVIEW MORE THAN 200,000 DIRECT OUTLET COVERAGE Type of outlet coveraged by the company s distribution Covers all trade channels in the market : General / Traditional Trade Channel Wholesalers Retailers Provision Stores Convenience Stores Food & Beverage Store - Fruit Shops Cosmetic Stores etc Modern Trade Channel Hypermarkets Supermarkets Mini Markets Departement Stores etc Pharmaceutical Trade Channel Pharmacies Drugstores Hospitals Labs Clinics Institutions etc 18

19 2017 OVERVIEW SALES CONTRIBUTION BY CHANNEL (Sept 2016 VS Sept 2017) 2016 Pharmaceutical Trade Modern Trade General Trade 2017 Pharmaceutical Trade General Trade Modern Trade 20,04% 36,58% 18,84% 35,86% 43,37% 45,30% 19

20 2017 OVERVIEW SALES CONTRIBUTION BY PRINCIPAL (Sept 2016 VS Sept 2017) External Principal Internal Principal External Principal Internal Principal 27% 27% 73% 73% 20

21 BUSINESS OVERVIEW THE COMPANY S MODERN TRADE ACCOUNT 21

22 BUSINESS OVERVIEW 200,000+ DIRECT OUTLET COVERAGE Covers all trade channels in the market: - General / Traditional Trade Channel: Wholesalers, Retailers, Provision Stores, Convenience Stores, Food & Beverage Stores, Fruit Shops, Cosmetics Stores, etc - Modern Trade Channel: Hypermarkets, Supermarkets, Mini Markets, Department Stores, etc - Ethical Trade Channel: Pharmacies, Drugstores, Hospitals, Labs - Clinics, Institutions, etc Provision Store; F&B Stores; Cosmetics; Others; Pharmacy; Hospital; Drugstore; Wholesaler; Hypermarket, 178 Supermarket; Minimarket;

23

24

25 OPERATIONAL OVERVIEW IT INFRASTRUCTURE Mobile application (Tablet Computer & PDA) - Supervisor: Team Performance Analysis. - Salesman & Deliveryman: Faster Order Taking & Faster Information Process. Global Information System (GIS) - Application for more in depth sales and territory mapping. Supported by Enseval Customer Care (ECC) HOTLINE In Branches Order Management, Complaint Handling, Basic Product Information. Customers also can reach Enseval office via Phone, Fax & for easy customer ordering. 25

26 OPERATIONAL OVERVIEW IT INFRASTRUCTURE Centralized IT system using Oracle E-Business Solutions Integrated & Real Time system Use the best world-class ERP system by Oracle Complete Oracle E-Business Suite Oracle Warehouse Management System (WMS) Advance Supply Chain Planning (ASCP) and Oracle Demantra Tablet Computer & PDA system E-Mobile 2,300+ PDA used by Supervisors, Salesmen, Deliverymen, & Collectors Menu: Distribution Plan, Distribution Achievement, Overdue, etc Provide data security for antivirus by Trend Micro and Sonic Wall 26

27 OPERATIONAL OVERVIEW COMPREHENSIVE BUSINESS ACCESS ENI (Enseval Net Info) Web based application Sales (hourly updated) & Stock (D-1) EXI (Enseval Xpress Info) SMS based application Sales & Stock Report ERI (Enseval Raw Data Info) Raw Data format, distribution and logistics information activities ENO (Enseval NET Order) EMOS (Enseval Mobile Order System) Online order with business-to-business system For Principal For Customer 27

28

29 FINANCIAL OVERVIEW NET SALES GROWTH Net Sales COGS 4,48% 88,92% 0,69% 89,61% 5,29% , , , ,84 Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) : Net Sales in Rp/billion : COGS in Rp/billion : Net Sales in Rp/billion : COGS in Rp/billion : COGS Margin 29

30 FINANCIAL OVERVIEW EXPENSE RATIO Gross Profit Operational Expense 11,08% (0,69)% 10,39% 7,93% (0,32)% 7,61% (2,02)% 0,29% 1.545, , , ,37 Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Gross Profit (Rp/billion) Gross Profit Margin Operational Expense (Rp/billion) Operational Expense Margin 30

31 FINANCIAL OVERVIEW PROFIT GROWTH (Sept 2016 VS Sept 2017) 3,16% Operating Profit (0,38)% 2,78% Income Before Income Tax Expense (0,51)% 3,56% 3,05% (7,83)% (10,56)% Income For The Period (0,39)% 2,71% 2,32% (10,42)% 439,82 405,37 496,21 443,82 377,10 337,80 Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Sept 30, 2016 (Unaudited) Sept 30, 2017 (Unaudited) Operating Profit (Rp/billion) Operating Profit Margin Income Before Income Tax Expense (Rp/billion) Income Before Tax Expense Margin Income For The Period Margin 31

32 FINANCIAL OVERVIEW FINANCIAL POSITION (Dec 2016 VS Sep 2017) 1,31% 7,22% 7.087, , ,29 (9,76)% 2.226, , ,54 Dec 31, 2016 (Audited) Sept 30, 2017 (Unaudited) Dec 31, 2016 (Audited) Sept 30, 2017 (Unaudited) Dec 31, 2016 (Audited) Sept 30, 2017 (Unaudited) Total Assets (Rp/billion) Total Liabilities (Rp/billion) 32

33

34 WAREHOUSE MANAGEMENT SYSTEM -Oracle-based WMS -Manage stock from inbound-outbound, by location, SKU, Batch Number, Expiry Date. -Bar-coding system with mobile bar-code reader to eliminate duplication & increase accurate operation. 34

35 COLD CHAIN MANAGEMENT -Enseval has implemented and Standardized Cold Chain Management in it s RDC, Branch Warehouse, and Transportation according to ISO 9001: Cold Chain Management is performed with close control -All activities is always recorded and stored properly Cold Chain Handling in Enseval Delivery with Temperature Controlled Transportation Temperature Monitoring Document 35

36 STANDARDIZED FACILITIES STANDARDIZED BRANCHES (FULL SERVICES) 36

37 STRATEGIC VALUE TO BUSINESS PARTNERS Market Leading Position in Indonesia Reliable Partner to Grow Transparency and Neutrality Strong product portfolio. Sustainable business growth. Supported by 2 RDC, 47 branches, 29 Sales Office & 200,000+ direct coverage outlets. 40+ years of strategic expertise in distribution and logistics service. Strong and good relationship with all business players : Principals & Outlets. Having in aggregate over 100 years of experience senior management team and supported by more than 5,000 employees. Public listed company with professional management that treats all business partners equally with the utmost transparency and accountability. Independent business entity with neutrality to ensure fairness to all stakeholders. Strong Financial Track Record Robust balance sheet figures. Solid financial performance. Enseval s Commitment Towards Improvement Commitment to assist & support Principal to achieve it s goals. Implementation of Continuous Improvement (CONIM) in all business aspects by Enseval s employees in every level. 37

38 THANK YOU For Further Information: Corporate Secretary PT Enseval Putera Megatrading Tbk. Enseval Building Kawasan Industri Pulogadung Jalan Pulolentut No. 10 Jakarta Indonesia Phone : Fax : Website : investor.relations@enseval.com

39 FORWARD LOOKING STATEMENT This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading Tbk. ("Enseval" or the "Company") This presentation has been prepared solely for use in connection with the release 0f 30 Sept 2017 (unaudited) results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representative shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are become generally avaiable as public information in accordance with prevailing laws regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by receipents to any other person. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation, including the information and opinions contained herein, is provided as the date of this presentation and is subject to change without notice, including change as a result of the issuance of 30 Sept 2017 unaudited results of the Company. This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", "estimate", "expect" and words of similiar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating to the Company's products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which of the Company will operate in the future. These forward-looking statements speak only ast the date of this presentation. The Company expressly disclaims any obligation or reflection of any change in the Company's expectations with regard thereto, or any change in events, conditions or circumtances on which any statements is based. Market data and certain industry forecast used in this presentation were obtained from market research, publicity avaiable information and industry publications which have not been independently verified, and no presentation is made as to the accuracy of such information.